Grilled Cheese

ExploreLog inSign up
Terms of UsePrivacy PolicyCommunity StandardsHelpGet the app

Grilled Cheese is a product of Village Compute

Version devBuilt at: 2026-10-12 04:31:30 EDT

Explore

PostsPeople
LatestRanked
Load more
@drtimos.bsky.socialOct 3, 2026, 6:56 PM

Signal or noise? > Vir Biotechnology (VIR) Could Be 48% Undervalued Following
Its CFO Appointment - Simply Wall Street >> Comment below! #strategy #competitiveintelligence #marketing #biotech #pharma #pharmaceutical #healthcare #competitivemarketing

@drtimos.bsky.socialOct 3, 2026, 5:26 PM

Signal or noise? > Ultragenyx Gets EMA Validation for Sanfilippo Gene Therapy -
grafa.com >> Comment below! #strategy #competitiveintelligence #marketing #pharmaceutical #competitivemarketing #pharma #healthcare #biotech

@abangelabs.bsky.socialOct 3, 2026, 4:03 PM

EMA has set the next CTIS build priorities around the Biotech Act and accelerated assessment. https://www.mattheneus.com/editorial/ema-ctis-biotech-act-accelerated-assessment-modernisation-2026-10-01 #HTA #RegulatoryAffairs #Pharma

@abangelabs.bsky.socialOct 3, 2026, 12:03 PM

Germany finalizes the legacy combination-discount register following statutory repeal. #HTA #RegulatoryAffairs #Pharma https://www.mattheneus.com/editorial/g-ba-annex-xiia-combination-discount-final-validity-register-2026-10-01

@drtimos.bsky.socialOct 3, 2026, 9:19 AM

Accelerate success in #Pharma & #Biotech!

🔬 Join LucidQuest on YouTube for #insights across therapeutic areas, as well as #ArtificialIntelligence, #MachineLearning, #DigitalHealth & more.

Subscribe & shape the future of #healthcare: http://dlvr.it/TVlxXP 🚀

#Strategy

@topnewsde.bsky.socialOct 3, 2026, 9:13 AM

#Bayer #Forschung #Milliarden #Ohio #Pharma #USA
🌐 www.newsmart.ch

@abangelabs.bsky.socialOct 3, 2026, 6:02 AM

Project Orbis cases reveal where faster Canadian regulatory review still leaves a critical HTA and access handoff. #HTA #RegulatoryAffairs #Pharma https://www.mattheneus.com/editorial/project-orbis-canada-regulatory-hta-access-handoff-2026-10-02

@drtimos.bsky.socialOct 3, 2026, 5:59 AM

Signal or noise? > Scientists "edited" a gene and halved "bad" cholesterol –
the effect has lasted for a year already - Українські Національні
Новини (УНН) >> Comment below! #strategy #competitiveintelligence #marketing #healthcare #biotech #competitivemarketing #pharmaceutical #pharma

@drtimos.bsky.socialOct 3, 2026, 2:29 AM

Signal or noise? > Ultragenyx says EMA validates MPS IIIA application -
mugglehead.com >> Comment below! #strategy #competitiveintelligence #marketing #healthcare #pharmaceutical #biotech #competitivemarketing #pharma

@abangelabs.bsky.socialOct 2, 2026, 9:03 PM

Germany found a small added benefit for Zynyz in first-line anal cancer. Here is what the final G-BA resolution means. https://www.mattheneus.com/editorial/g-ba-retifanlimab-anal-cancer-small-added-benefit-podium303-final-resolution-2026-10-01 #HTA #RegulatoryAffairs #Pharma

@abangelabs.bsky.socialOct 2, 2026, 9:03 PM

One fluoxetine outlier distorted two Lancet networks. A three-analysis reappraisal shows why trial influence matters. https://www.mattheneus.com/editorial/pubmed-fluoxetine-paediatric-depression-outlier-trial-nma-reappraisal-2026-10-02 #HTA #NMA #EvidenceSynthesis #Pharma

@pharmalot.bsky.socialOct 2, 2026, 5:59 PM

Up and Down the Ladder: Job Changes.. the latest comings & goings.. recognize anyone? statnews.com/pharmalot/20... #pharma #biotech #jobs

@2eubrussels.bsky.socialOct 2, 2026, 5:00 PM

The Council has adopted the EU pharma package. New medicines would normally receive 8 years of data protection + 1 year of market protection, with incentives taking the combined period up to 11 years. Member States could also impose supply obligations. #Pharma #EUHealth

@abangelabs.bsky.socialOct 2, 2026, 4:03 PM

Germany’s Zynyz appraisal shows how uncertainty can leave added benefit unquantifiable. #HTA #Pharma https://www.mattheneus.com/editorial/g-ba-zynyz-merkel-cell-carcinoma-added-benefit-unquantifiable-2026-10-01

@pharmaphorum.bsky.socialOct 2, 2026, 3:27 PM

In today’s headlines: pharmaphorum.com/news #news #pharma #lifesciences #pharmanews #pharmaindustry

@midgardfinance.comOct 2, 2026, 12:30 PM

💊 #pharma #EASD2026

🇺🇸 $LLY #orforglipron on major heart events vs insulin: hazard ratio 0.77 (0.52-1.13). Too small a trial to prove a benefit.

Not head to head: tirzepatide 0.92 vs dulaglutide; 🇩🇰 $NOVO #semaglutide pill 0.86, injection 0.80 vs placebo.

midgardfinance.com/cardiovascular/

Forest plot of hazard ratios for major heart events (heart attack, stroke or cardiovascular death) in four outcome trials of incretin drugs, on a log axis with a vertical line at 1; left of the line means fewer events than the comparison arm. The rows are in two groups because the trials were run against different things. Tested against placebo, in light blue: Semaglutide injection against placebo (SELECT, 17,604 patients): 0.80, interval 0.72 to 0.90. Semaglutide pill against placebo (SOUL, 9,650 patients): 0.86, interval 0.77 to 0.96. Tested against another drug, in purple: Tirzepatide against dulaglutide (SURPASS-CVOT, 13,299 patients): 0.92, interval 0.83 to 1.01. Orforglipron pill against insulin glargine (ACHIEVE-4, 2,749 patients): 0.77, interval 0.52 to 1.13. Orforglipron's estimate lies among the others, but its interval is about 4 times as wide and crosses 1: its trial was sized to rule out harm, which it did, not to prove a benefit. These are separate trials, not head-to-head comparisons. Dulaglutide is itself a heart-protective drug, so a ratio against it cannot be set beside a ratio against placebo, and SELECT enrolled people without diabetes while the other three enrolled people with type 2 diabetes. For orforglipron this is the three-part endpoint; its primary endpoint, which also counts hospitalisation for unstable angina, was 0.84 with an interval of 0.59 to 1.20.
@abangelabs.bsky.socialOct 2, 2026, 12:04 PM

Denmark issues new CTIS submission guidance for complex clinical trials and seasonal vaccine studies. #HTA #RegulatoryAffairs #Pharma https://www.mattheneus.com/editorial/danish-medicines-agency-complex-clinical-trial-seasonal-vaccine-ctis-guidance-2026-10-02

@abangelabs.bsky.socialOct 2, 2026, 12:03 PM

EMA sets 2026 year-end submission dates for Type I variations, helping regulatory teams plan upcoming filings. #HTA #RegulatoryAffairs #Pharma https://www.mattheneus.com/editorial/ema-type-i-variation-end-year-submission-dates-2026-10-01

@abangelabs.bsky.socialOct 2, 2026, 9:02 AM

Sweden’s Alhemo decision shows how HTA can reconcile a difficult bleeding endpoint with cost evidence. https://www.mattheneus.com/editorial/tlv-alhemo-concizumab-haemophilia-b-explorer8-cost-comparison-2026-10-02 #HTA #HealthEconomics #Pharma

@longevitytech.bsky.socialOct 2, 2026, 8:23 AM

What could pharma’s shift towards prevention mean for therapeutics?

The Longevity Biotech Report 2026 tracks $30bn+ invested, 3,036 therapeutics and 781 companies shaping the market.

Access the report free. Link in the comment.

Sponsored by MuseCell Innovations.

#Longevity #Pharma #Biotech